<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02577783</url>
  </required_header>
  <id_info>
    <org_study_id>SZ5202</org_study_id>
    <nct_id>NCT02577783</nct_id>
  </id_info>
  <brief_title>PDD vs PAD to Treat Initially Diagnosed MM</brief_title>
  <official_title>Doxorubicin Hydrochloride Liposome vs Doxorubicin Combined With Bortizomib and Dexamethasone to Treat Initially Diagnosed Multiple Myeloma: A Randomized Prospective Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether doxorubicin hydrochloride liposome is
      superior to doxorubicin when combined with bortizomib and dexamethasone for treating patient
      with initially diagnosed multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>4 cycles (each cycle is 28 days) of chemotherapy</time_frame>
    <description>sCR + CR + VGPR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall remission rate</measure>
    <time_frame>4 cycles (each cycle is 28 days) of chemotherapy</time_frame>
    <description>sCR + CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>PDD arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients involved in PDD arm will accept chemotherapy of PDD regimen (doxorubicin hydrochloride liposome plus bortizomib and dexamethasone )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAD arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients involved in PAD arm will accept chemotherapy of PAD regimen (doxorubicinplus bortizomib and dexamethasone )</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy with PDD regimen</intervention_name>
    <description>doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)</description>
    <arm_group_label>PDD arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy with PAD regimen</intervention_name>
    <description>doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)</description>
    <arm_group_label>PAD arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed and untreated multiple myeloma patients

          -  Patients with age between 18 and 70 years

          -  With a evaluable disease

          -  ECOG score ≤2

          -  NE≥1.0×10E9 /L, Plt≥50×10E9 /L, Hb≥70 g/L

          -  AST, ALT, ALP≤3×ULN, serum BIL≤ULN

          -  LVEF≥ 50%

          -  Not in pregnancy

          -  Written informed consent are acquired

        Exclusion Criteria:

          -  Severe heart failure (NYHA grade II or higher)

          -  Active and uncontrolled severe infection

          -  HIV positive

          -  Have accepted any other anti-tumor drug within 30 days before the first dose of
             doxorubicin hydrochloride iposome or doxorubicin

          -  Grade 2 or higher peripheral neuropathy before treatment

          -  Have suffered any other malignancy in past 5 years

          -  Females in lactation

          -  Other situations that investigators consider as contra-indication for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Chen, M.D.</last_name>
      <phone>+86 512 67781856</phone>
      <email>chenjiasuzhou@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Doxorubicin Hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

